Impact of Cryopreservation Methods on Post-Thaw SARS-CoV-2 in Semen Samples
NCT ID: NCT06703723
Last Updated: 2024-11-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
40 participants
OBSERVATIONAL
2021-01-14
2021-04-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The burden of the SARS-CoV-2 virus has rapidly evolved. SARS-CoV-2 causes respiratory, cardiovascular, digestive, and urinary infections, yet no studies have explored its effects on the reproductive system. Recent findings confirm the expression of the virus receptor (ACE2) on certain testicular cells, including Sertoli cells, Leydig cells, and spermatogonia, which could significantly impact fertility and cryopreservation practices.
This study aims to utilize semen samples from individuals exposed to SARS-CoV-2 infection to perform two different cryopreservation procedures, evaluating virus behavior and effects. The objective is to determine whether it is safer to cryopreserve the entire volume of the sample or perform gradient separation to isolate the virus from spermatozoa, potentially establishing a new cryopreservation protocol specific to SARS-CoV-2.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Human Sperm Markers of Cryodamage Resistance
NCT02535377
Effect of Long-time Human Sperm Storage in Liquid Nitrogen on Semen Parameters
NCT06448000
Impact of the Coronavirus Disease 2019 (COVID-19) on Sperm Parameters
NCT04937608
Testicular Tissue Cryopreservation (TTC)
NCT06387498
Presence of SARS-CoV-2 (COVID-19) in Semen: Impact on Fertility Preservation in Male Oncological Patients ?
NCT04487639
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
No current evidence confirms whether SARS-CoV-2 can survive semen cryopreservation, though other viruses, such as influenza, have demonstrated survival in liquid nitrogen freezing. Semen cryopreservation is a critical fertility preservation strategy for conditions like cancers, autoimmune diseases, or cryptorchidism. The contamination of cryopreserved semen by SARS-CoV-2 could turn such samples into hazardous viral reservoirs.
The study aims to investigate the presence of the virus in semen, identify cells expressing viral receptors ACE2 and TMPRSS2, and evaluate the virus's direct and indirect effects on male reproductive capacity. Objectives include determining if SARS-CoV-2 survives cryopreservation procedures and identifying optimal methods to ensure virus-free cryopreserved semen while separating infected material from male gametes.
The study will recruit 20 men exposed to SARS-CoV-2 and 20 control subjects, all treated at the Humanitas Fertility Center, Department of Gynecology, at the Humanitas Research Hospital. Each participant will provide a semen sample for evaluation. This observational study will not involve clinical interventions or alter regular diagnostic procedures.
Participants undergoing routine tests for medically assisted reproduction and deemed eligible after completing an anamnesis questionnaire will be included. Samples will be processed in the Mucosal Immunology and Microbiota Unit at the Humanitas Clinical Institute.
Using cell biology, molecular biology, and flow cytometry techniques, the study will assess viral contamination, receptor expression in spermatozoa, and inflammatory cytokine levels in seminal fluid after two cryopreservation methods: slow two-step freezing and vitrification. Analyses will cover unprocessed semen and samples exposed in vitro to SARS-CoV-2 under BSL3 conditions.
Additionally, the cellular fraction of semen, including granulocytes, lymphocytes, round cells, and spermatozoa, will undergo phenotype and activation state characterization. The study will evaluate viral contamination in cryopreserved semen and assess the effectiveness of protocols designed to separate infected material from male gametes.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Male subjects, aged 18-50 requiring a semen fluid evaluation. • Positive IgG serological test result
No interventions assigned to this group
Healthy
Healthy
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Positive IgG serological test result performed not more than 3 months before recruitment
* Signed informed consent
* Anamnestic test compilation
* Male subjects, aged 18-50 requiring a semen fluid evaluation.
* Negative IgG serological test result performed within the last month
* Signed informed consent
* Anamnestic test compilation
Exclusion Criteria
* Fever (\>38.5 C) in the 60 days before enrollment
* Treated with antibiotic at the time of enrolment or two months before enrolment
* Treated with cortisone at the time of enrolment or two months before enrolment
* Severe male Factor (azoospermia and \<200,00 sperm per ejaculate)
* Fever (\>38.5 C) in the 60 days before enrolment
* Known history of SARS-CoV-2 infection
* Treated with antibiotic at the time of enrolment or two months before enrolment
* Treated with cortisone at the time of enrolment or two months before enrolment
18 Years
50 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Istituto Clinico Humanitas
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Istituto Clinico Humanitas
Rozzano, Milan, Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
230879
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.